Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

V. Wacheck · SciRah

Researcher profile · Semantic Scholar

V. Wacheck

Share profile

V. Wacheck — researcher profile on SciRah

h-index: 38
Works: 134
Citations: 4,941

Most-cited papers

Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.
L. Goyal, F. Meric-Bernstam, A. Hollebecque, J. Valle +26 more
2023New England Journal of Medicine505 citations Open access
Semantic Scholar
Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
K. Aichberger, M. Mayerhofer, M. Krauth, H. Skvara +11 more
2005Blood262 citations Open access
Semantic Scholar
Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy.
W. Sieghart, D. Losert, S. Strommer, D. Cejka +7 more
2006Journal of Hepatology232 citations Open access
Semantic Scholar
Expression of the target receptor CD33 in CD34+/CD38−/CD123+ AML stem cells
A. Hauswirth, S. Florian, D. Printz, K. Sotlar +7 more
2007European Journal of Clinical Investigation154 citations
Semantic Scholar
Mammalian Target of Rapamycin Pathway Activity in Hepatocellular Carcinomas of Patients Undergoing Liver Transplantation
W. Sieghart, T. Fuereder, K. Schmid, D. Cejka +7 more
2007Transplantation152 citations Open access
Semantic Scholar
A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1.
V. Wacheck, A. Egorov, Franz Groiss, A. Pfeiffer +18 more
2010Journal of Infectious Diseases130 citations Open access
Semantic Scholar
Short interfering RNA (siRNA): tool or therapeutic?
D. Cejka, D. Losert, V. Wacheck
2006Clinical science110 citations
Semantic Scholar
LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth
Ling Liu, Wei Zeng, Mark A. Wortinger, S. Yan +18 more
2014Clinical Cancer Research103 citations Open access
Semantic Scholar
A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer
J. Bendell, A. Varghese, D. Hyman, T. Bauer +8 more
2018Clinical Cancer Research84 citations Open access
Semantic Scholar
Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo
D. Cejka, M. Preusser, A. Woehrer, W. Sieghart +4 more
2008Cancer Biology & Therapy73 citations Open access
Semantic Scholar
A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-line Treatment for EGFR-mutation Positive NSCLC Patients.
G. Scagliotti, D. Moro-Sibilot, J. Kollmeier, A. Favaretto +15 more
2019Journal of Thoracic Oncology70 citations Open access
Semantic Scholar
Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412.
K. Aichberger, M. Mayerhofer, K. Gleixner, M. Krauth +8 more
2007Blood70 citations Open access
Semantic Scholar
Innovation in oncology clinical trial design.
J. Verweij, H. Hendriks, H. Zwierzina, Hanauske +8 more
2019Cancer Treatment Reviews69 citations
Semantic Scholar
Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth
Michele C. Smith, M. Mader, James A. Cook, P. Iversen +11 more
2016Molecular Cancer Therapeutics69 citations Open access
Semantic Scholar
A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer
L. Rosen, J. Goldman, A. Algazi, P. K. Turner +7 more
2016Clinical Cancer Research62 citations Open access
Semantic Scholar
Characterization of NVX‐207, a novel betulinic acid‐derived anti‐cancer compound
M. Willmann, V. Wacheck, J. Buckley, K. Nagy +5 more
2009European Journal of Clinical Investigation60 citations
Semantic Scholar
Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo.
J. Werzowa, Stefan Koehrer, S. Strommer, D. Cejka +3 more
2011Journal of Investigative Dermatology57 citations Open access
Semantic Scholar
Antisense molecules for targeted cancer therapy.
V. Wacheck, U. Zangemeister-Wittke
2006Critical reviews in oncology/hematology56 citations
Semantic Scholar
Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements.
L. Goyal, F. Meric-Bernstam, A. Hollebecque, C. Morizane +16 more
2022Journal of Clinical Oncology48 citations
Semantic Scholar
mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivo.
T. Fuereder, Agnes Jaeger-Lansky, D. Hoeflmayer, M. Preusser +5 more
2010Cancer Letters46 citations
Semantic Scholar
FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo
Daniel Cejka, C. Kuntner, M. Preusser, M. Fritzer-szekeres +9 more
2009British Journal of Cancer45 citations Open access
Semantic Scholar
Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer
C. Sweeney, I. Percent, S. Babu, J. Cultrera +15 more
2022Clinical Cancer Research40 citations Open access
Semantic Scholar
MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping
S. Yan, S. Um, V. Peek, J. Stephens +6 more
2017Investigational new drugs40 citations Open access
Semantic Scholar
Gastric Cancer Growth Control by BEZ235 In Vivo Does Not Correlate with PI3K/mTOR Target Inhibition but with [18F]FLT Uptake
T. Fuereder, T. Wanek, Pamina Pflegerl, Agnes Jaeger-Lansky +9 more
2011Clinical Cancer Research36 citations
Semantic Scholar
mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo.
D. Cejka, M. Preusser, T. Fuereder, W. Sieghart +3 more
2008Anticancer Research34 citations
Semantic Scholar
A Phase 1b/2 Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer
J. Harding, A. Zhu, T. Bauer, T. Choueiri +10 more
2019Clinical Cancer Research31 citations Open access
Semantic Scholar
A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer
D. Sakai, H. Chung, D. Oh, S. Park +11 more
2017Cancer Chemotherapy and Pharmacology30 citations Open access
Semantic Scholar
A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein expressing murine breast cancer
T. Wanek, C. Kuntner, J. Bankstahl, M. Bankstahl +9 more
2011European Journal of Nuclear Medicine and Molecular Imaging30 citations Open access
Semantic Scholar
Mcl-1 is a relevant molecular target for antisense oligonucleotide strategies in gastric cancer cells
V. Wacheck, D. Cejka, W. Sieghart, D. Losert +4 more
2006Cancer Biology & Therapy29 citations Open access
Semantic Scholar
A randomized, open-label, phase 2 study of emibetuzumab plus erlotinib (LY+E) and emibetuzumab monotherapy (LY) in patients with acquired resistance to erlotinib and MET diagnostic positive (MET Dx+) metastatic NSCLC.
D. Camidge, T. Morán, I. Demedts, H. Grosch +13 more
201628 citations
Semantic Scholar
The PI3-Kinase/mTOR-Targeting Drug NVP-BEZ235 Inhibits Growth and IgE-Dependent Activation of Human Mast Cells and Basophils
K. Blatt, H. Herrmann, I. Mirkina, E. Hadzijusufovic +12 more
2012PLoS ONE27 citations Open access
Semantic Scholar
Bcl-2 downregulation sensitizes nonsmall cell lung cancer cells to cisplatin, but not to docetaxel
D. Losert, Barbara Pratscher, J. Soutschek, A. Geick +3 more
2007Anti-Cancer Drugs26 citations
Semantic Scholar
Sphingosine kinase 1 is a relevant molecular target in gastric cancer
T. Fuereder, D. Hoeflmayer, Agnes Jaeger-Lansky, Doris Rasin-Streden +5 more
2011Anti-Cancer Drugs25 citations
Semantic Scholar
MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis
H. S. Kim, H. Chon, Hyunki Kim, Su-Jin Shin +5 more
2018Journal of Surgical Oncology23 citations Open access
Semantic Scholar
A clinical trial on absorption and N‐acetylation of oral and rectal mesalazine
Karin Dilger, D. Trenk, M. Rössle, M. Cap +6 more
2007European Journal of Clinical Investigation23 citations Open access
Semantic Scholar
A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib.
D. Camidge, T. Morán, I. Demedts, H. Grosch +11 more
2022Clinical Lung Cancer20 citations Open access
Semantic Scholar
Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma
M. Zauderer, E. Alley, J. Bendell, E. Capelletto +7 more
2021Investigational new drugs20 citations Open access
Semantic Scholar
Phenotyping of Human Melanoma Cells Reveals a Unique Composition of Receptor Targets and a Subpopulation Co-Expressing ErbB4, EPO-R and NGF-R
I. Mirkina, E. Hadzijusufovic, C. Krepler, M. Mikula +8 more
2014PLoS ONE17 citations Open access
Semantic Scholar
First-in-human dose escalation study of LY2875358 (LY), a bivalent MET antibody, as monotherapy and in combination with erlotinib (E) in patients with advanced cancer.
J. Goldman, L. Rosen, A. Algazi, P. K. Turner +4 more
201317 citations
Semantic Scholar
Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma
Jerry T. Wu, A. Cheuk, Kristine A Isanogle, C. Robinson +23 more
2023Cancers13 citations Open access
Semantic Scholar
A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies
K. Yoh, T. Doi, H. Ohmatsu, Takashi Kojima +7 more
2016Investigational new drugs10 citations Open access
Semantic Scholar
Phase 1b/2 study of enzalutamide (ENZ) with LY3023414 (LY) or placebo (PL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone.
C. Sweeney, I. Percent, S. Babu, J. Cultrera +16 more
2019Journal of Clinical Oncology9 citations
Semantic Scholar
Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo
Agnes Jaeger-Lansky, D. Cejka, L. Ying, M. Preusser +4 more
2010Cancer Biology & Therapy9 citations Open access
Semantic Scholar
Incidence and Management of Olaratumab Infusion-Related Reactions
B. Van Tine, R. Govindarajan, S. Attia, N. Somaiah +7 more
2019Journal of Oncology Practice8 citations Open access
Semantic Scholar
A phase I, first-in-human dose study of the dual PI3K/mTOR inhibitor LY3023414 (LY) in patients (pts) with advanced cancer.
K. Moore, A. Varghese, D. Hyman, S. Callies +5 more
20158 citations
Semantic Scholar
Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer
S. Kondo, M. Tajimi, Tomohiko Funai, Koichi Inoue +4 more
2020Investigational new drugs7 citations Open access
Semantic Scholar
Abstract A55: Phase 1 results of emibetuzumab (LY2875358), a bivalent MET antibody, in patients with advanced castration-resistant prostate cancer, and MET positive renal cell carcinoma, non-small cell lung cancer, and hepatocellular carcinoma
Michaela S. Banck, R. Chugh, R. Natale, A. Algazi +11 more
20157 citations
Semantic Scholar
Characterization of NKIP: a novel, Na+/K+-ATPase interacting protein mediates neural differentiation and apoptosis.
Barbara Pratscher, C. Friedrich, Wilfried Goger, Matthew Allen +11 more
2008Experimental Cell Research7 citations
Semantic Scholar
[Oligonucleotide therapeutics - an emerging novel class of compounds].
V. Wacheck
2006Wiener Medizinische Wochenschrift7 citations
Semantic Scholar
A phase I, open‐label, single‐dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib
Ling Gao, I. Yamamiya, Mark Pinti, J. Rondón +5 more
2023Clinical and Translational Science6 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

S. Strommer×12
Invite
S. Strommer — researcher profile on SciRah
T. Fuereder×10
Invite
T. Fuereder — researcher profile on SciRah
D. Cejka×9
Invite
D. Cejka — researcher profile on SciRah
X. Wang×7
Invite
X. Wang — researcher profile on SciRah

×6

Invite

J. Werzowa — researcher profile on SciRah

Invite

J. Bendell — researcher profile on SciRah

Invite

E. Selzer — researcher profile on SciRah

Invite

W. Sieghart — researcher profile on SciRah

D. Hoeflmayer×5

Invite

D. Hoeflmayer — researcher profile on SciRah

Invite

S. Callies — researcher profile on SciRah

S. Wijayawardana×5

Invite

S. Wijayawardana — researcher profile on SciRah

Invite

P. Valent — researcher profile on SciRah